10-Q: Zai Lab Q3 2025: Revenue Growth Amidst Pipeline Progress

Zai Lab reports a 13% increase in Q3 2025 net product revenue, driven by NUZYRA and XACDURO sales, alongside significant clinical advancements and a reduced net loss.

Summary

• Net product revenue for the third quarter of 2025 increased by 13% to $115.4 million compared to the prior year period.
• Total revenues for the third quarter of 2025 were $116.1 million, a 14% increase year-over-year.
• Net loss for Q3 2025 improved by 14% to $36.0 million, down from $41.7 million in Q3 2024.
• For the nine months ended September 30, 2025, net product revenue grew 14% to $330.1 million, and total revenues increased 15% to $332.6 million.
• Net loss for the nine months ended September 30, 2025, was $125.1 million, a 29% improvement from $175.4 million in the same period of 2024.
• Research and development (R&D) expenses decreased by 27% to $47.9 million in Q3 2025 and by 13% to $159.3 million for the nine months, primarily due to lower licensing fees and personnel costs.
• Selling, general, and administrative (SG&A) expenses increased by 4% to $70.1 million in Q3 2025 but decreased by 5% to $204.6 million for the nine months.
• Cash and cash equivalents, current restricted cash, and short-term investments totaled $817.2 million as of September 30, 2025.
• Key product performance highlights include NUZYRA sales up 54% and OPTUNE sales up 64% in Q3 2025, with XACDURO and AUGTYRO contributing as new launches.
• ZEJULA sales were softer, decreasing by 12% in Q3 2025 due to evolving competitive dynamics.
• Clinical advancements include positive Phase I data for Zocilurtatug Pelitecan (Zoci) in ES-SCLC, Hong Kong approval for Tisotumab Vedotin (TIVDAK), Innovative Medical Device Designation for TTFields therapy in pancreatic cancer, and positive topline results for Efgartigimod (VYVGART) in AChR-Ab seronegative gMG.
• The Phase III FORTITUDE-101 follow-up analysis for bemarituzumab showed attenuated survival benefit, and the FORTITUDE-102 study was stopped.

Sentiment

Score: 7

Explanation: The company showed strong revenue growth and a significant reduction in net loss, indicating improved financial health and operational efficiency. Pipeline advancements and regulatory approvals are positive. However, the decline in ZEJULA sales due to competition and the discontinuation of a bemarituzumab study are notable headwinds. The increased short-term debt and potential need for future funding are also factors. Overall, the progress in reducing losses and advancing the pipeline outweighs the challenges.

Positives

• Net product revenue increased by 13% to $115.4 million in Q3 2025 and by 14% to $330.1 million for the nine months ended September 30, 2025.
• Net loss significantly improved, decreasing by 14% to $36.0 million in Q3 2025 and by 29% to $125.1 million for the nine months ended September 30, 2025.
• NUZYRA sales grew by 54% to $15.4 million in Q3 2025, driven by increasing market coverage and penetration.
• OPTUNE sales increased by 64% to $12.7 million in Q3 2025.
• XACDURO and AUGTYRO are new commercial launches contributing to revenue.
• Research and development expenses decreased by 27% in Q3 2025 and 13% for the nine months, reflecting resource prioritization and efficiency.
• Positive Phase I data for Zocilurtatug Pelitecan (Zoci) in ES-SCLC, showing a 68% overall response rate in 2L patients at 1.6 mg/kg dose and 80% in patients with untreated brain metastases, with a well-tolerated safety profile.
• Tisotumab Vedotin (TIVDAK) received approval in Hong Kong for recurrent or metastatic cervical cancer.
• TTFields therapy received Innovative Medical Device Designation from the NMPA for pancreatic cancer, with plans for regulatory filing in mainland China in Q4 2025, based on positive Phase III PANOVA-3 trial results.
• Efgartigimod (VYVGART) met its primary endpoint in the ADAPT SERON study for AChR-Ab seronegative gMG, demonstrating statistically significant and clinically meaningful improvement.
• Xanomeline-Trospium (KarXT) was included in the China Schizophrenia Prevention and Treatment Guidelines (2025 Edition), marking the first national-level guideline globally to include it, and its NDA was accepted by NMPA in January 2025.
• Povetacicept (Pove) received FDA Breakthrough Therapy Designation for IgA nephropathy.
• Strengthened global leadership team with the appointment of Dr. Shan He as Senior Vice President, Chief Business Officer.
• Established an Oncology Scientific Advisory Board (SAB) to support oncology pipeline advancement.
• Sufficient capital of $817.2 million (cash, cash equivalents, restricted cash, short-term investments) to fund operations for at least the next 12 months.

Negatives

• ZEJULA sales were softer, decreasing by 12% to $42.4 million in Q3 2025 and 4% to $133.0 million for the nine months, due to evolving competitive dynamics within the PARPi class.
• Bemarituzumab's Phase III FORTITUDE-101 follow-up analysis showed an attenuated magnitude of previously observed survival benefit (median OS of 14.5 months versus 13.2 months, compared to 17.9 months versus 12.5 months at interim analysis).
• FORTITUDE-102, a Phase Ib/III study for bemarituzumab, was stopped.
• Interest income decreased by 8% in both the three and nine months ended September 30, 2025, due to decreased interest rates.
• Interest expenses increased significantly by 88% to $1.4 million in Q3 2025 and 185% to $3.8 million for the nine months, primarily due to higher levels of short-term debt.
• Foreign currency gains decreased by 56% to $6.4 million in Q3 2025.
• Other income (expense), net, shifted from a net income of $3.4 million in Q3 2024 to a net expense of $0.5 million in Q3 2025, primarily due to a decrease in government grants.
• Net cash used in operating activities was $124.8 million for the nine months ended September 30, 2025.

Risks

• Ability to successfully commercialize and generate revenue from approved products.
• Ability to obtain funding for operations and business initiatives.
• Results of clinical and pre-clinical development of product candidates.
• Content and timing of regulatory decisions and approvals.
• Reliance on third parties (licensors, CMOs, CROs, distributors) to carry out contractual duties or meet deadlines.
• Chinese manufacturing facilities' conformity with GMPs and international best practices, and passing inspections (FDA, NMPA, EMA).
• Inability to obtain or maintain sufficient patent or regulatory data protection.
• Changes in U.S. and China trade policies, relations, laws, regulations, and/or sanctions.
• Actions the Chinese government may take to intervene in or influence operations.
• Economic, political, and social conditions in mainland China and governmental policies.
• Significant business disruptions (pandemics, war, natural disasters, geopolitical events).
• Uncertainties in the Chinese legal system, including anti-corruption efforts and various data/cybersecurity/biosecurity laws.
• Approval, filing, or procedural requirements by Chinese regulatory authorities for issuing securities to foreign investors.
• Violation or liability under U.S. Foreign Corrupt Practices Act or Chinese anti-corruption laws.
• Variations in currency exchange rates and restrictions on currency exchange.
• Limitations on Chinese subsidiaries' ability to make payments to the parent company.
• Chinese requirements on residents in mainland China to establish offshore special purpose companies.
• Chinese regulations regarding acquisitions of companies based in mainland China by foreign investors.
• Expiration of, or changes to, financial incentives or discretionary policies granted by local governments in mainland China.
• Restrictions or limitations on overseas regulators to conduct investigations or collect evidence within mainland China.
• Unfavorable tax consequences if classified as a Chinese resident enterprise for Chinese income tax purposes.
• Failure to comply with applicable Chinese, U.S., and Hong Kong regulations.
• Delays or obstacles for closing transactions, such as CFIUS review.
• Inability to renew current leases on desirable terms or locate alternatives.
• Competitive dynamics within the PARPi class affecting ZEJULA sales.
• Attenuated survival benefit observed in follow-up analysis for bemarituzumab in gastric cancer.
• Stopping of FORTITUDE-102 study for bemarituzumab.
• Potential for future milestone and royalty payments under license agreements, totaling up to $211.0 million for current clinical programs, $366.0 million for other programs, and $1,753.0 million in sales-based milestones.

Future Outlook

Zai Lab expects product revenue to increase in coming years by enhancing patient access through NRDL listing or increased supplemental insurance coverage and by launching additional commercial products upon regulatory approvals. The company plans to continue significant investments in research and development to advance and expand its pipeline. Regulatory filing for TTFields therapy in mainland China is planned for Q4 2025, and a potential China regulatory submission for Efgartigimod in AChR-Ab seronegative gMG is under consideration. A global registrational study for zoci monotherapy in 2L+ SCLC has been initiated, along with a global Phase I/Ib study for ZL-1503 in atopic dermatitis. The company anticipates financial results will fluctuate based on commercial product success and R&D expenses, and cannot predict the timing or success of future regulatory approvals or commercialization efforts.

Management Comments

• We intend to leverage our competencies and resources to positively impact human health.
• Developing high quality product candidates requires significant investment in our research and development activities over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area.
• Our ability to generate profits and positive cash flow from operations depends upon our ability to successfully market our commercial products and to successfully expand the indications for these products and develop and commercialize our other product candidates.
• As we pursue our corporate strategic goals, we anticipate that our financial results will fluctuate from quarter to quarter and year to year depending in part on the balance between the success of our commercial products and the level of our research and development expenses.
• We cannot predict whether or when our product candidates will receive regulatory approval. Further, if we receive such regulatory approval, we cannot predict whether or when we may be able to successfully commercialize such products or whether or when such products may become profitable.
• We expect our product revenue to increase in coming years as we continue to focus on increasing patient access to our existing commercial products, such as through NRDL listing or increased supplemental insurance coverage in the private-pay market, and as we launch additional commercial products, if and when we obtain required regulatory approvals.
• Such development and regulatory milestone payments are contingent on the progress of our product candidates prior to commercialization, and we see these payments as favorable because they indicate that product candidates are advancing.
• Such sales-based milestone and royalty payments are contingent on the performance of our commercial products, and we see these payments as favorable because they signify that a product is achieving higher sales levels.
• Although we believe that we have sufficient capital to fund our operations for at least the next twelve months, we may, from time to time, utilize debt arrangements on favorable commercial terms or consider additional funding sources to bring to fruition our strategic objectives.

Industry Context

Zai Lab operates in highly competitive biopharmaceutical sectors including oncology, immunology, neuroscience, and infectious disease. The company's focus on Greater China highlights the importance of regional market access strategies, such as NRDL listing and supplemental insurance, for commercial success. The competitive dynamics observed with ZEJULA in the PARPi class reflect broader industry challenges for established products facing new entrants. Conversely, the inclusion of KarXT in China's schizophrenia guidelines and FDA Breakthrough Therapy Designation for Povetacicept demonstrate global and regional recognition of innovative therapies. The attenuated results and discontinuation of a bemarituzumab study underscore the inherent high-risk nature of late-stage drug development, even for promising candidates, a common challenge across the industry.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The Company is not currently a party to any material legal proceedings.

Related Party Transactions

• In January 2025, the Company entered into a license agreement with Zenas BioPharma (HK) Limited (Zenas) to develop and commercialize products containing a differentiated humanized monoclonal antibody targeting IGF-1R in Greater China.
• Mr. Moulder, a member of Zai Lab's Board of Directors, is also the Chairman of the Board of Directors and Chief Executive Officer of Zenas.
• The Company recorded a $10.0 million upfront fee into research and development expenses in the first quarter of 2025 related to the Zenas agreement.
• As of September 30, 2025, the Company may be required to pay an additional aggregate amount of up to $117.0 million in development and sales-based milestones, as well as certain royalties at tiered percentage rates ranging from high-single digits to mid-teens on annual net sales of the licensed products in the licensed territories.

Stakeholder Impact

• Shareholders: Improved net loss and revenue growth could positively impact shareholder sentiment. Dilution from share-based compensation and potential future capital raises are factors.
• Employees: Resource prioritization and efficiency efforts in R&D and SG&A could imply workforce adjustments, though personnel compensation decreased in R&D but increased in SG&A for Q3. Share-based compensation continues to be a significant component.
• Customers: Increased market coverage and penetration for products like NUZYRA and VYVGART, along with new product launches, indicate broader access to therapies.
• Suppliers/Partners: Continued reliance on CROs/CMOs/Investigators for clinical trials and collaboration partners for product supply and development. Milestone payments indicate ongoing collaboration.
• Creditors: Increased short-term debt and new credit facilities indicate ongoing borrowing, but the company states sufficient capital for 12 months.

Next Steps

• Initiate a global registrational study of zoci monotherapy in 2L+ SCLC.
• Submit an sBLA to the FDA seeking expansion of the VYVGART label to include adult AChR-Ab seronegative gMG patients (by partner argenx).
• Consider a potential China regulatory submission for Efgartigimod in AChR-Ab seronegative gMG.
• File for regulatory approval for TTFields therapy in mainland China in the fourth quarter of 2025.
• Initiate a global Phase I/Ib study to evaluate safety, tolerability, and pharmacokinetics of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis.
• Continue to focus on increasing patient access to existing commercial products through NRDL listing or increased supplemental insurance coverage.
• Launch additional commercial products upon obtaining required regulatory approvals.
• Continue making significant investments in research and development, including internal discovery activities.
• Monitor and manage potential future milestone payments for clinical, other, and sales-based programs.

Key Dates

Recommendation

Zai Lab demonstrates strong revenue growth in several key commercial products and a notable reduction in net loss, indicating improved operational efficiency and a path towards profitability. The pipeline continues to advance with positive clinical data and regulatory milestones for several candidates, particularly Zoci, VYVGART, and TTFields. However, the competitive pressures impacting ZEJULA sales and the setbacks with bemarituzumab highlight ongoing risks in drug development and commercialization. While the company has sufficient liquidity for the near term, the increased reliance on short-term debt and potential future funding needs warrant caution. The mix of strong commercial performance and pipeline progress, balanced against competitive and development risks, suggests a 'Hold' recommendation for investors to monitor the execution of pipeline advancements and market penetration strategies.

Keywords

Biopharmaceutical, Oncology, Immunology, Neuroscience, Infectious Disease, SEC Filing, 10-Q, Zai Lab, ZEJULA, VYVGART, NUZYRA, OPTUNE, QINLOCK, XACDURO, AUGTYRO, Zocilurtatug Pelitecan, Tisotumab Vedotin, Bemarituzumab, Tumor Treating Fields, ZL-1503, Efgartigimod, Xanomeline-Trospium, Povetacicept, Clinical Trials, Regulatory Approval, China Market, Drug Development, Financial Results